MTOR and colorectal carcinoma: Given the inhibitory effect of DIS3L2 KD in cell viability, we explored a potential target of DIS3L2 among genes that clustered in the mTOR pathway, and we found AZGP1, whose mTOR inhibitory activity has been previously documented in different cancer types, including CRC [44–46].